OSE Immunotherapeutics, a biotechnology company, which is a member of the Atlanpole Biotherapies cluster and which develops immunotherapy for activation and regulation in immuno-oncology, in autoimmune diseases and transplantation, won the 1st Deloitte In Extenso Technology Fast 50 Prize as well as the “Société Côtée” Prize.
The ranking of the results takes into account the turnover growth rate over the last four years. OSE Immunotherapeutics was awarded the “Société Cotée” Prize for the very strong increase of its growth rate of +1900% between 2012 and 2015.
On 14 November, Frédéric Boiffin of Enternext and Jean-Marc Sevault of Atlanpole were delighted to present the award to Dominique Costantini, General Manager and Maryvonne Hiance, Vice-President of the company.
